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ART ICLE Open Ac ce s s
Long non-coding RNA ZFAS1 is a major regulator
of epithelial-mesenchymal transition through
miR-200/ZEB1/E-cadherin, vimentin signaling in
colon adenocarcinoma
Stephen J. O’Brien1, Casey Fiechter1, James Burton1, Jacob Hallion1, Mason Paas1, Ankur Patel1, Ajay Patel1,
Andre Rochet1, Katharina Scheurlen1, Sarah Gardner1, Maurice Eichenberger1, Harshini Sarojini1, Sudhir Srivastava 2,3,
Shesh Rai2, Theodore Kalbfleisch 4, Hiram C. PolkJr1 and Susan Galandiuk 1
Abstract
Colon adenocarcinoma is a common cause of cancer-related deaths worldwide. Epithelial-mesenchymal transition is a
major regulator of cancer metastasis, and increased understanding of this process is essential to improve patient
outcomes. Long non-coding RNA (lncRNA) are important regulators of carcinogenesis. To identify lncRNAs associated
with colon carcinogenesis, we performed an exploratory differential gene expression analysis comparing paired colon
adenocarcinoma and normal colon epithelium using an RNA-sequencing data set. This analysis identified lncRNA
ZFAS1 as significantly increased in colon cancer compared to normal colon epithelium. This finding was validated in
an institutional cohort using laser capture microdissection. ZFAS1 was also found to be principally located in the
cellular cytoplasm. ZFAS1 knockdown was associated with decreased cellular proliferation, migration, and invasion in
two colon cancer cell lines (HT29 and SW480). MicroRNA-200b and microRNA-200c (miR-200b and miR-200c) are
experimentally validated targets of ZFAS1, and this interaction was confirmed using reciprocal gene knockdown.
ZFAS1 knockdown regulated ZEB1 gene expression and downstream targets E-cadherin and vimentin. Knockdown of
miR-200b or miR-200c reversed the effect of ZFAS1 knockdown in the ZEB1/E-cadherin, vimentin signaling cascade,
and the effects of cellular migration and invasion, but not cellular proliferation. ZFAS1 knockdown was also associated
with decreased tumor growth in an in vivo mouse model. These results demonstrate the critical importance of ZFAS1
as a regulator of the miR-200/ZEB1/E-cadherin, vimentin signaling cascade.
Introduction
Colorectal cancer is a major cause of cancer-related
death worldwide1. Although large cohort studies
demonstrate that early detection with screening is asso-
ciated with earlier stage at diagnosis and improved
survival, many patients still present with advanced stage
(Stage III or IV) disease2. Increased understanding of the
complex processes involved in tumor metastasis are cri-
tical to identifying potential treatment targets and
improving patient outcomes.
Epithelial-mesenchymal transition (EMT) is a normal
part of embryological development but is also a well
characterized and critical part of tumor metastasis3.
Colorectal cancers that demonstrate a mesenchymal
phenotype have worse clinical outcomes compared to
those with an epithelial phenotype4. EMT is a reversible
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process whereby cells lose key morphological and phe-
notypic epithelial features and gain mesenchymal features.
The process is regulated by both genetic and epigenetic
factors, such as non-coding RNA regulation. Elucidation
of such factors specific to colorectal cancer are needed to
develop more sophisticated screening tools and targeted
therapies, thereby improving patient outcomes.
Long-non coding RNA (lncRNA) are a class of mole-
cules that have recently been described to have a major
role in cancer signaling5. They mediate their effect
through a number of different mechanisms of action. The
molecular decoy, or competitive endogenous RNA
mechanism, is frequently described. With this mechan-
ism, lncRNAs can competitively bind molecules such as
microRNA (miRNA), and prevent them from mediating
their effect on downstream gene signaling. ZFAS1 is a
lncRNA on chromosome 20 and has been examined in
different cancers but variable results have been reported6.
A recent review described that the majority of studies
report that ZFAS1 has an oncogenic role, but ZFAS1 has a
tumor suppressor role in breast cancer, and conflicting
mechanisms have been reported in hepatocellular cancer6.
It is important to examine the role of lncRNAs in indi-
vidual cancer types. The miR-200 family is a well char-
acterized regulator of EMT in cancer that has been
demonstrated in a number of in vitro and human studies4.
The miR-200 family is a group of five miRNAs and its
core mechanism is regulated through a double-negative
feedback loop with ZEB1/ZEB2 expression7.
In this study, we describe the identification and valida-
tion of lncRNA ZFAS1 as having an important role in
colon cancer progression using a large RNA-seq data set
and institutional clinical samples. ZFAS1 was increased in
expression in CRC tissue compared to normal colon
epithelium across all data sets examined. ZFAS1 knock-
down was associated with decreased cellular proliferation,
migration, and invasion. In examining the mechanism of
action, ZFAS1 was able to regulate Zinc-finger E-box
binding homeobox 1 (ZEB1) expression by altering miR-
200b and miR-200c signaling. Therefore, ZFAS1 may be a
potential future therapeutic target.
Results
ZFAS1 is a highly differentially expressed lncRNA in colon
adenocarcinoma compared to normal colon epithelium
Using the colon adenocarcinoma TCGA data set, we
identified 40 patients with paired colon adenocarcinoma
and normal colon epithelium RNA-seq data files. A dif-
ferential gene expression analysis was performed to
identify dysregulated lncRNAs between the paired cancer
and normal colon epithelium samples. Using a log fold
change of >1.5 or <−1.5, and a false discovery rate <0.05,
348 lncRNAs were found to be differentially expressed
(Supplementary Fig. 1).
To narrow the lncRNAs for further investigation, the
Cancer Cell Line Encyclopedia was interrogated for
colon cancer cell lines with robust lncRNA expres-
sion8. lncRNAs were also selected on the basis of
having experimentally validated lncRNA-miRNA
interactions on the DIANA lncBASE platform, as
well as reports in the literature9. From this, seven
lncRNA were selected for further investigation:
FAM83H-AS1, PVT1, UCA1, H19, FER1L4, GAS5,
and ZFAS1.
Previous studies have shown that the tumor micro-
environment can skew data analysis by “contaminat-
ing” gene expression in macrodissected tumor
samples10,11. Therefore, laser capture microdissection
was used to investigate lncRNA expression in 23
patients with paired colon adenocarcinoma and normal
colon epithelium samples (Table 1, Fig. 1a). Three of
the seven lncRNAs (PVT1, GAS5, and ZFAS1) were
significantly upregulated and two (FAM83H-AS1 and
UCA1) were significantly downregulated in colon
adenocarcinoma compared to paired normal colon
epithelium samples (Fig. 1b). ZFAS1 was the most
significantly increased lncRNA in our validated data set
and was therefore selected for further investigation
(Fig. 1c). ZFAS1 was significantly increased in expres-
sion in three separate sequencing data sets compared
to normal tissue (all p < 0.05) (Fig. 1d–f). As expected,
increased ZFAS1 expression was associated with both
copy number gain and amplification (Fig. 1g). There
was, however, no difference in the overall survival of
the TCGA clinical cohort between high and low ZFAS1
expression (Fig. 1h).
Table 1 Clinical details of patients from the University of
Louisville Biorepository.
Variable N= 23 N (%)








Stage I 7 (30)
Stage II 6 (26)
Stage III 5 (22)
Stage IV 5 (22)
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ZFAS1 knockdown is associated with a less aggressive
phenotype
ZFAS1 was principally located in the cellular cyto-
plasm of all three cell lines (Fig. 2a). There was robust
ZFAS1 knockdown in all three cell lines (all > 70% and
p < 0.05), without a decrease in cellular viability com-
pared to non-target siRNA (all p > 0.05) (Fig. 2b, c).
ZFAS1 knockdown was associated with decreased
cellular proliferation (Fig. 2d, e) in the HT29 and SW480
cell lines. There was, however, no difference in Caco2
cellular proliferation comparing ZFAS1 knockdown to
non-target siRNA, which is likely due to the inherent
slow doubling time of the Caco2 cell line12. Therefore,
for further functional experiments, we focused on the
HT29 (epithelial-like) and the SW480 cell line
(mesenchymal-like). As such, ZFAS1 knockdown was
Fig. 1 Characterization of lncRNA expression in the TCGA data set and in an institutional data set, with a specific focus on ZFAS1.
a Example of a hematoxylin and eosin slide that was used as a guide for laser capture microdissection of the tissue from the University of Louisville
Biorepository. b Fold regulaton of each of the seven selected lncRNAs examined by RTqPCR from LCM tissue from the University of Louisville
Biorepository; FAM83H-AS1 (FR=−3.68, *p < 0.001), FER1L4 (FR=−2.22 p= 0.12), GAS5 (FR= 1.70, **p= 0.021), H19 (FR=−1.67, p= 0.84), PVT1
(FR= 2.75, ***p= 0.003), UCA1 (FR=−4.85, *p < 0.001), ZFAS1 (FR= 3.06, *p < 0.001), (n= 23 paired samples). c Scatter plot of ZFAS1 expression in
colon cancer compared to paired normal colon epithelium examined by RTqPCR from LCM tissue from the University of Louisville Biorepository (n=
23 paired institutional samples) (FC= 3.06, *p < 0.001). d Heatmap comparing the differential expression (RSEM quantification) between paired colon
adenocarcinoma and normal colon epithelium of the seven lncRNAs using RNAseq expression data from the Cancer Genome Atlas (n= 40 paired
samples). e Increased ZFAS1 expression in cancer compared to paired normal colon epithelium in the GEO GSE95132 RNA-seq dataset (n= 10 paired
samples, RNA-seq expression, units=TPM) (Ϯp= 0.009). f Increased expression of ZFAS1 in cancer compared to paired normal colon epithelium in the
GEO GSE104836 RNA-seq dataset (n= 10 paired samples, units= normalized RNAseq expression) (Ϯp= 0.009). g Increased expression of ZFAS1 in
colon cancer compared to unpaired colon epithelium in the GEO GSE103512 array dataset (n= 70 Affymetrix array expression, units= normalized
Affymetrix array) (*p < 0.001). h There is increased ZFAS1 expression with copy number gain and copy number amplification compared to diploid in
the RNAseq TCGA data set (n= 388) (*p < 0.001, Ϯp < 0.009). i There is no difference in the overall clinical patient survival between high and low
ZFAS1 expression in the RNAseq TCGA data set (n= 192) (RNA-seq expression data dichotomized on basis of median expression) (p= 0.11). All
RTqPCR experiments were run in duplicate.
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associated with decreased transwell migration and inva-
sion (Fig. 2f–i) and a slower scratch assay closure (Fig. 2j, k)
in the HT29 and SW480 cell lines. As expected, both
transwell assays and scratch closure demonstrated slower
migration of the HT29 cell line compared to the SW480
cell line. This is likely due to the HT29 cell line having an
epithelial-like Consensus Molecular Subtype 3 (CMS3)
compared to the mesenchymal-like CMS4 of the SW480
cell line12.
Investigation of experimentally validated miRNA targets of
ZFAS1
As previously mentioned, there are experimentally
validated lncRNA-miRNA interactions for ZFAS1 (Table 2)
(refs. 13–20). Following ZFAS1 knockdown, expression of
both miR-200b and miR-200c was significantly increased
compared to non-target siRNA (Fig. 3a, b). The lncRNA-
miRNA binding sites from the DIANA lncBASE platform
are shown in Fig. 3c, d. ZFAS1 was inversely correlated
with miR-200c (Spearman r=−0.120, p= 0.09), but not
inversely correlated with miR-200b (Spearman r=
−0.030, p= 0.65) in the TCGA data set (Fig. 3e, f).
Although ZFAS1 does not inversely correlate with miR-
200b, lncRNA and miRNA expression are dependent on a
number of different upstream regulatory molecules21. We
have previously reported the adverse role of low miR-200b
and miR-200c expression with overall survival22. Both
mir-200b and miR-200c are increased in colorectal cancer
compared to paired normal colon epithelium. In addition,
both miR-200b and miR-200c are decreased in expression
in Stage III/IV compared to Stage I/II colon cancer.
Furthermore, transfection with either miR-200b or miR-
200c mimics leads to decreased ZFAS1 expression in the
both the HT29 and SW480 cell lines (Fig. 3g–j). The
direct binding interaction between ZFAS1 and miR-200b
between miR-200c has been shown previously through
both RNA immunoprecipitation15 and an RNA pulldown
assay16. This defined interaction was examined for sub-
sequent mechanistic and functional assays.
ZFAS1 knockdown is associated with changes in the ZEB1
and is mediated through miR-200b and miR-200c signaling
Previous studies have demonstrated the major role of
the miR-200 family in cancer signaling, particularly in
EMT regulation4. Transfection with either ZFAS1 siRNA,
miR-200b, or miR-200c mimics leads to ZEB1 mRNA
knockdown in both the HT29 and SW480 cell lines
(see figure on previous page)
Fig. 2 Characterization of ZFAS1 function in vitro. a ZFAS1 is principally located in the cytoplasm, compared to the nucleus, measured by RTqPCR
in all three colon cancer cell lines (HT29: 76% vs. 24%, p= 0.02, SW480: 84% vs. 16%, p= 0.03, Caco2: 77% vs. 23%, p= 0.005, n= 6 replicates).
b RTqPCR shows efficient knockdown of ZFAS1 with ZFAS1 siRNA in all three cell lines compared to non-target siRNA (all > 70%, all *p < 0.05, n= 6
replicates). c There is no decrease in the cell viability (percentage of viable cells compared to all counted cells) with ZFAS1 knockdown compared to
cells transfected with non-target siRNA (n= 6 replicates). d There is significant decrease in the cellular proliferation with ZFAS1 knockdown in the
HT29 cell lines, by examining the doubling time (34.3 h vs. 30.6 h, p= 0.046), the individual counts at 96 h (**p= 0.03), and the counts at 120 h
(***p= 0.02) (n= 6 replicates). e There is significant decrease in the cellular proliferation with ZFAS1 knockdown in the SW480 cell lines, by
examining the doubling time (42.5 h vs. 31.5 h, p= 0.01), and the individual counts at 72 h (**p= 0.03), 96 h (**p= 0.03), and 120 h (Ϯp= 0.01) (n= 6
replicates). f There is significantly decreased migration of cells with ZFAS1 knockdown in the HT29 cell line (***p= 0.02, n= 6 replicates) The panels
on the right show representative ×10 magnification fields of the HT29 cell line transwell migration assay (top panel ZFAS1 knockdown, bottom panel
non-target siRNA). g There is significantly decreased migration of cells with ZFAS1 knockdown in the SW480 cell line (**p= 0.03, n= 6 replicates). The
panels on the right show representative ×10 magnification fields of the SW480 cell line transwell migration assay (top panel ZFAS1 knockdown,
bottom panel non-target siRNA). h There is significantly decreased invasion of cells with ZFAS1 knockdown in the HT29 cell line (***p= 0.02, n= 6
replicates) The panels on the right show representative ×10 magnification fields of the HT29 cell line transwell invasion (top panel ZFAS1 knockdown,
bottom panel non-target siRNA). i There is significantly decreased invasion of cells with ZFAS1 knockdown in the SW480 cell line (**p= 0.03, n= 6
replicates). The panels on the right show representative ×10 magnification fields of the SW480 cell line transwell invasion (top panel ZFAS1
knockdown, bottom panel non-target siRNA). j There was a significantly slower scratch closure of the HT29 cell line with ZFAS1 knockdown
compared to control (ϮϮp= 0.004, n= 11 replicates). The panels on the right show representative ×4 magnification fields of the HT29 scratch assay
(top panels scratch closure following ZFAS1 knockdown at time 0 and at 120 h, bottom panels scratch closure with non-target siRNA at time 0 and at
120 h). k There was a signficiantly slower scratch closure of the SW480 cell lines with ZFAS1 knockdown compared to control (ϮϮϮp < 0.001, n= 6
replicates). The panels on the right show representative ×4 magnification fields of the SW480 scratch assay (top panels scratch closure following
ZFAS1 knockdown at time 0 and at 48 h, bottom panels scratch closure with non-target siRNA at time 0 and at 48 h).





ZFAS1 miR-200b Liu G. et al.13 RNA immunoprecipitation
Zhang F et al.14 RNA pulldown assay
miR-200c Liu G. et al.13 RNA immunoprecipitation
miR-150 Xia B. et al.15 Luciferase reporter assay
Li T. et al.16 RNA pulldown assay
Wu T. et al.17 RNA pulldown assay
Chen X et al.18 RNA pulldown assay
miR-484 Xie S et al.19 RNA immunoprecipitation
miR-27a Ye Y et al.20 RNA pulldown assay
Luciferase reporter assay
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(Fig. 4a, b). ZFAS1 knockdown, in turn, leads to decreased
ZEB1 protein expression in both cell lines (Fig. 4c, d).
Furthermore, dual knockdown of ZFAS1 and miR-200b or
ZFAS1 and miR-200c reversed this effect on ZEB1
expression in both the HT29 and SW480 cell lines. As
miR-200b and miR-200c act directly on ZEB1, pro-
nounced effects are seen on ZEB1 expression with miRNA
mimics and antagomirs.
Increased ZFAS1 expression and decreased miR-200b or
miR-200c expression is associated with adverse clinical
outcomes, and ZFAS1 mediates its effect on the E-cadherin
vimentin signaling through miR-200b and miR-200c
signaling
As previously mentioned, ZFAS1 expression alone is
not associated with adverse clinical outcomes. However,
when ZFAS1 expression is stratified by both miR-200b
(Fig. 5a, b) and miR-200c expression (Fig. 5c, d), high
ZFAS1 expression is associated with worse overall survival
in the setting of low miR-200b (p= 0.018) and low miR-
200c (p= 0.048) expression. This suggests that patients
with high ZFAS1 expression and low miR-200b or low
miR-200c expression have a particularly poor genomic
signature. As hypothesized, downstream of ZEB1, ZFAS1
knockdown leads to increased E-cadherin expression as
well as decreased vimentin protein expression (Fig. 5e–h)
in both the HT29 and SW480 cell lines. This regulatory
effect on E-cadherin and vimentin expression was atte-
nuated with dual transfection of ZFAS1 and miR-200b or
ZFAS and miR-200c in both the HT29 and SW480 cell
lines. Interestingly, we did not observe an increase in the
E-cadherin expression with miR-200b or miR-200c mimic
transfection. There is low endogenous expression of ZEB1
in the HT29 cell line, and this may explain the inability of
Fig. 3 Examination of the interactions between ZFAS1 and target miRNAs. a ZFAS1 knockdown leads to increased miR-200b (FC= 3.34, *p=
0.01) and miR-200c (FC= 2.28, **p= 0.012) expression using RTqPCR in the HT29 cell line (n= 6 replicates). b ZFAS1 knockdown leads to increased
miR-200b (FC= 6.69, ***p= 0.005) and miR-200c (FC= 6.53, Ϯp= 0.022) expression using RTqPCR in the SW480 cell line (n= 6 replicates). c The
experimentally validated site of interaction between ZFAS1 and miR-200b is shown. d The experimentally validated site of interaction between ZFAS1
and miR-200c is shown. e Using the Cancer Genome Atlas data set, miR200c was inversely correlated with ZFAS1 expression (n= 199, RNA-seq and
miRNA-seq expression data) (Spearman r= 0.120, p= 0.09. f Using the Cancer Genome Atlas, miR200b was not inversely correlated with ZFAS1
expression (n= 199, RNA-seq and miRNA-seq expression data) (Spearman r= 0.03, p= 0.65). g Following transfection with miR-200b mimics, there is
signficantly decreased ZFAS1 expression using RTqPCR at 48 (FR=−2.33, ϮϮp= 0.001) and 72 (FR=−2.074, ϮϮϮp= 0.008) hours after transfection (n
= 6 replicates). h Following transfection with miR-200c mimics, there is signficantly decreased ZFAS1 expression using RTqPCR at 24 (FR=−1.74, γ p
= 0.041), 48 (FR=−2.53, γγ p= 0.015) and 72 (FR=−2.78, γγγ p= 0.026) hours after transfection in the HT29 cell line (n= 6 replicates). i Following
transfection with miR-200b mimics, there is signficantly decreased ZFAS1 expression using RTqPCR at 48 (FR=−2.33, ѱp= 0.033) and 72 (FR=
−1.46, ѱѱp= 0.02) hours after transfectionin the SW480 cell line (n= 6 replicates). j Following transfection with miR-200c mimics, there is
significanlty decreased ZFAS1 using RTqPCR at 48 (FR=−1.99, ѱѱѱp= 0.03) and 72 (FR=−1.64, λ p= 0.02) in the SW480 cell line (n= 6 replicates).
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miR-200b or miR-200c to indirectly regulat E-cadherin
expression. This explanation may also account for the
differences seen in vimentin expression in the HT29 cell
line.
miR-200b and miR-200c knockdown partially reverse the
functional effect of ZFAS1 knockdown on proliferation,
migration, and invasion
To validate these signaling cascade results, we per-
formed functional cellular assays with dual knockdown
of both ZFAS1 and miR-200b or ZFAS1 and miR-200c.
In the HT29 cell line, there was no difference in cellular
proliferation with dual knockdown of ZFAS1 and miR-
200b compared to non-target. However, there was a
significant difference in the doubling time of cells with
dual knockdown of ZFAS1 and miR-200c compared to
non-target (Fig. 6a, Supplementary Table 4). In the
SW480 cell line, there was no difference in the doubling
time following ZFAS1 and miR-200c knockdown com-
pared to non-target, but there were significant differ-
ences in the individual cell counts at 96 h (p= 0.003)
and 120 h (p= 0.02). Following knockdown with ZFAS1
and miR-200b, there was a slower doubling time of cells
as compared to non-target (Fig. 6b, Supplementary
Table 4). In both cell lines, under both conditions, there
was no difference in the transwell migration or invasion
compared to non-target (all p > 0.05) (Fig. 6c–f). In the
HT29 cell line, there was a significant difference in the
scratch closure of cells following dual ZFAS1 and miR-
200c knockdown compared to non-target (p= 0.02), but
there was no difference in the dual ZFAS1 and miR-
200b knockdown. In addition, there was no difference in
the scratch closure in either of the SW480 dual knock-
down conditions (Fig. 6g, e).
ZFAS1 knockdown is associated with decreased tumor
growth in vivo
Previous experiments describe the clinical relevance and
the mechanisms of action of ZFAS1 in colorectal cancer
cell lines, but it is important to explore its mechanism of
action in vivo. Using a mouse model, ZFAS1 knockdown
was associated with decreased tumor volume compared to
non-target siRNA (Fig. 7a). A summary of the results of
this study are illustrated in Fig. 7b.
Discussion
We hypothesized that using a RNA-sequencing data set to
compare the entire transcriptome of colon adenocarcinoma
Fig. 4 ZFAS1 knockdown is associated with changes in ZEB1 expression. This effect is reversed by dual knockdown of ZFAS1 and miR200b or
with ZFAS1 and miR200c. a In the HT29 cell line, ZFAS1 knockdown (FR=−2.68, *p= 0.031), miR-200b mimics (FR=−3.19, **p= 0.03), or miR-200c
mimics (FR=−1.82, ***p= 0.04) leads to decreased ZEB1 mRNA expression using RTqPCR (n= 6 replicates). b In the SW480 cell line, ZFAS1
knockdwon (FR=−3.37, Ϯp= 0.034), miR-200b mimics (FR=−12.24, Ϯp < 0.001), or miR-200c mimics (FR=−10.1, ϮϮp < 0.001) knockdown leads to
decreased ZEB1 mRNA expression using RTqPCR (n= 6 replicates). c There is significantly decreased ZEB1 protein expression with ZFAS1 knockdown
(ϮϮϮp= 0.046) in the HT29 cell line by Western blotting. This effect was reversed by dual knockdown of either ZFAS1 and miR200b or ZFAS1 and
miR200c (both p > 0.05). As expected, miR200b and miR200c antagomirs increased ZEB1 expression, with reciprocal decreased in ZEB1 expression
with miR-200b and miR200c mimics (n= 5 replicates). d Similarly, there is significantly decreased ZEB1 protein with ZFAS1 knockdown in the SW480
cell line by Western blotting (γ p= 0.047). This effect was reversed by dual knockdown of either ZFAS1 and miR200b or ZFAS1 and miR200c (both
p > 0.05). As expected, miR200b and miR200c antagomirs increased ZEB1 expression, with reciprocal decreased in ZEB1 expression with miR-200b
and miR200c mimics (n= 5 replicates).
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tissue to paired normal colon epithelium tissue would allow
us to investigate differentially expressed lncRNAs that are
critical in colorectal carcinogenesis. We validated the
expression of ZFAS1, identifying it as a major regulator of
tumor progression in CRC, through the critical miR-200/
ZEB1/E-cadherin, vimentin signaling cascade.
There are variable results when examining ZFAS1 as a
mediator of carcinogenesis in the literature6. ZFAS1 has
been shown to have a tumor suppressive function in
breast cancer by decreasing cellular proliferation and
migration23,24. In hepatocellular carcinoma, ZFAS1 can
have both a tumor suppressive and oncogenic function.
Fig. 5 Colon cancer patients with high ZFAS1 and low miR-200b or miR-200c expression have worse overall survival. The effect of ZFAS1
knockdown on E-cadherin and vimentin expresison is reveresed by dual knockdown of ZFAS1 and miR200b or with ZFAS1 and miR200c. a
Using the TCGA RNAseq and miRNAseq expression data (n= 199), there is no difference in the overall survival of colon cancer patients with high
miR-200b expression (stratified by median expression) when stratified by ZFAS1 median expression (p= 0.95), (b) but there is a significant difference
in the overall survivial of colon cancer patients with low miR-200b expression when stratified by ZFAS1 expression (p= 0.018). c There is no
difference in the overall survival of colon cancer patients with high miR-200c expression (stratified by median expression) when stratified by ZFAS1
expression (p= 0.81), (d) but there is a significant difference in the overall survivial of colon cancer patients with low miR-200c expression when
stratified by ZFAS1 median expression (p= 0.048). e There is significantly increased E-cadherin protein with ZFAS1 knockdown (*p= 0.022) in the
HT29 cell line by Western blotting. This effect was reversed by dual knockdown of either ZFAS1 and miR200b or ZFAS1 and miR200c (both p > 0.05).
As expected, transfection with miR200b and miR200c antagomirs reduces E-cadherin expression (both p < 0.05). Transfection with both miR200b and
miR200c mimics did not lead to the expected increase in E-cadherin expression (n= 5 replicates). f There is significantly decreased vimentin protein
with ZFAS1 knockdown (**p= 0.025) in the HT29 cell line by Western blotting. This effect was reversed by dual knockdown of either ZFAS1 and
miR200b or ZFAS1 and miR200c (both p > 0.05). Unexpectedly, miR200b and miR200c antagomirs did not lead to increased vimentin expression. As
expected, transfection with miR200b and miR200c mimics reduced vimentin expression (both p < 0.05) (n= 5 replicates). g There is significantly
increased E-cadherin protein with ZFAS1 knockdown (***p= 0.021) in the SW480 cell line by Western blotting. This effect was reversed by dual
knockdown of either ZFAS1 and miR200b or ZFAS1 and miR200c (both p > 0.05). As expected, transfection with miR200b and miR200c antagomirs
reduces E-cadherin expression (both p < 0.05). Transfection with miR200b and miR200c mimics leads to increased E-cadherin expression (n= 5
replicates). h There is significantly decreased vimentin protein with ZFAS1 knockdown (Ϯp= 0.036) in the HT29 cell line by Western blotting. This
effect was reversed by dual knockdown of either ZFAS1 and miR200b or ZFAS1 and miR200c (both p > 0.05). miR200b and miR200c antagomirs led
to increased vimentin expression, but this was not statistically significant. Transfection with miR200b and miR200c mimics did not lead to decreased
vimentin expression (n= 5 replicates).
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For example, it can act as a tumor suppressor by
methylating miR-9 in hepatocellular carcinoma25, but can
also promote cancer metastasis through miR-150 bind-
ing16. The majority of studies, however, demonstrate that
ZFAS1 has an oncogenic function, many indicating that
ZFAS1 can regulate both proliferation and migration13,15.
Recently, Chen et al. reported that ZFAS1 could regulate
proliferation, migration, and invasion in colorectal can-
cer18. ZFAS1 could mediate an indirect regulation of
VEGFA by directly binding miR-150. The results of our
Fig. 6 (See legend on next page.)
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experiments support the functional data reported by Chen
et al, in that ZFAS1 knockdown leads to decreased pro-
liferation and migration. The direct binding interaction
between ZFAS1 and the miR-200 family has been shown
previously through different mechanistic assays including
RNA immunoprecipitation15 and RNA pulldown16. We
have validated this interaction in both colorectal cancer
patients and in colorectal cancer cell lines.
Interestingly, we also investigated the interaction with
miR-150, but we did not find a reciprocal expression
change. This finding contrasts with Chen et al., as they
reported that miR-150 had a direct binding interaction
with ZFAS1 in the HCT116 cell line. This explanation for
this discrepancy is unclear, however, and requires further
investigation. Nevertheless, both sets of data support the
concept that lncRNAs can have multiple mechanisms of
action through different signaling cascades. This attribute
has been described as both a positive and negative aspect
regarding their potential utility26,27.
Non-coding RNAs are being investigated as a small
molecule therapeutic strategy for different diseases. There
are a number of clinical trials exploring both miRNA and
siRNA technology as a therapeutic strategy28. For exam-
ple, a novel small molecule targeting miR-122 has been
effective in reducing RNA levels of hepatitis C virus in a
phase 2 clinical trial29. In the future, lncRNAs and other
non-coding RNAs may have a major role in the ther-
apeutic management of different diseases.
(see figure on previous page)
Fig. 6 Knockdown of miR-200b or miR-200c partially reverses the effect on proliferation, but reverses the effect on migration and
invasion. a In the HT29 cell line, there is no difference in cell proliferation following dual ZFAS1 and miR-200b knockdown compared to non-target
siRNA, when measured by doubling time (p= 0.46), but there is more rapid proliferation with dual knockdown of ZFAS1 and miR-200c compared to
non-target siRNA (*doubling time: 26.8 h vs. 30.6 h, p= 0.01) (n= 6 replicates). b In the SW480 cell line, cell proliferation following dual ZFAS1 and
miR-200b knockdown is slower than compared to non-target siRNA (**doubling time: 35.9 vs. 30.5, p= 0.06), but there was no difference in
proliferation with dual knockdown of ZFAS1 and miR-200c compared to non-target siRNA (p= 0.55) (n= 6 replicates). c, d In the HT29 and SW480
cell lines, there is no difference in the transwell migration with both ZFAS1 and miR-200b or ZFAS1 andmiR-200c knockdown compared to non-
target siRNA (all p > 0.05) (n= 6 replicates), The panels on the right of each figure show representative ×10 magnification fields of the HT29 and
SW480 cell lines transwell migration assay (top panel ZFAS1 knockdown + miR-200b antagomir, middle panel ZFAS1 knockdown + miR-200c
antagomir, bottom panel non-target siRNA). e, f In the HT29 and SW480 cell lines, there was no difference in the transwell invasion with both ZFAS1
and miR-200b or ZFAS1 and miR-200c knockdown compared to non-target siRNA (all p > 0.05) (n= 6 replicates). The panels on the right of each
figure show representative ×10 magnification fields of the HT29 and SW480 cell lines transwell migration assay (top panel ZFAS1 knockdown + miR-
200b antagomir, middle panel ZFAS1 knockdown + miR-200c antagomir, bottom panel non-target siRNA). g In the HT29 cell line, there was no
difference in scratch closure in both ZFAS1 and miR-200b or ZFAS1 and miR-200c knockdown compared to non-target siRNA (all p > 0.05) (n= 6
replicates). The panels on the right show representative ×4 magnification fields of the HT29 scratch assay (top panels scratch closure following dual
ZFAS1 and miR-200b knockdown at time 0 and at 120 h, middle panels scratch closure following dual ZFAS1 and miR-200c knockdown at time 0 and
120 h, bottom panels scratch closure with non-target siRNA at time 0 and at 120 h). h In the SW480 cell line, there was no difference in scratch
closure in both ZFAS1 and miR-200b or ZFAS1 and miR-200c knockdown compared to non-target siRNA (all p > 0.05) (n= 6 replicates). The panels on
the right show representative ×4 magnification fields of the SW480 scratch assay (top panels scratch closure following dual ZFAS1 and miR-200c
knockdown at time 0 and at 48 h, middle panels scratch closure following dual ZFAS1 and miR-200c knockdown at time 0 and 48 h, bottom panels
scratch closure with non-target siRNA at time 0 and at 48 h).
Fig. 7 ZFAS1 knockdown is associated with decreased tumor growth in vivo compared to not-target siRNA. a ZFAS1 knockdown was
associated with decreased tumor volume in a mouse xenograft model compared to non-target siRNA, with significant differenes observed from day
3 after mass was first identified in each mouse. The differences were most pronounced from day 7 up until day 14 when the experiment was
terminated (N= 4 replicates) (*p= 0.006, **p < 0.001, ***p= 0.024). b Illustration of the signaling cascade demonstrated by these results.
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Many studies demonstrate that miRNA can regulate
lncRNAs through the competitive endogenous RNA
mechanism, but few examine upstream regulators. We
report that there is copy number amplification seen with
ZFAS1 in the TCGA colon adenocarcinoma cohort.
Additionally, transcription factor, SP1, has been shown to
transcriptionally increase ZFAS1 in a number of different
cancer types6. This suggests that modulating specific
transcription factors adds a further layer of complexity
when studying the relationship between lncRNAs and
protein coding genes. This complex regulatory network
could partially explain why we do not find a clear inverse
relationship between ZFAS1 and miR200b or miR200c, as
a number of different upstream regulators can affect their
expression.
The results of these experiments highlight areas
requiring further investigation. There is some conflict
between the results from the TCGA differential gene
expression and our results from laser capture micro-
dissection. The tissue that is used for RNA-seq in the
TCGA data is from a macrodissected tumor sample.
Therefore, it includes not only cancer cells, but also other
cells from the tumor microenvironment10. Previous stu-
dies have shown that molecules, such as miRNA, can have
different expression, depending on the location from
which the RNA is extracted from a cancer specimen (e.g.,
superficial tumor, deep border etc)11,30. In addition, cells
from within the tumor microenvironment may express or
secrete lncRNAs in order to induce an effect on cancer
cells31. In this case, whole tissue dissection may lead to the
false conclusion that the lncRNA is expressed from the
cancer cells instead of from cells within the tumor
microenvironment. TGF-β is a major inducing agent of
EMT32, and recent studies have demonstrated that it can
be secreted by macrophages and other immune cells in
the tumor microenvironment33. This could be investi-
gated through the use of transwell chambers or by treat-
ing colon adenocarcinoma cell lines with cultured
macrophage secretions, as performed by Jahangiri et al.31.
Although our study demonstrates the role of
ZFAS1 signaling through regulation of miR-200b and
miR-200c, ZFAS1 interacts with a number of other
miRNAs, suggesting further work is required to fully
delineate the function of ZFAS1 and other lncRNAs.
There are a number of limitations to this work. As pre-
viously mentioned, lncRNAs can mediate an effect on a
number of different signaling pathways; however, we
focused on a single signaling pathway to help delineate the
mechanism of action of ZFAS1. There are five members of
the miR-200 family, and we restricted our study to two of
these, miR-200b and miR-200c, since they have been
experimentally verified to interact with ZFAS1. Although
miR-200b, miR-200c, and miR-429 are part of the same
functional cluster, we did not examine the role of miR-429,
as it was not an experimentally validated target of ZFAS1.
Further studies could investigate the role of other members
of the miR-200 family in relation to ZFAS1. Although we
selected lncRNAs that are increased in expression in colon
cancer compared to normal colon epithelium, there are a
large number of lncRNAs that are downregulated in
expression. Due to the large size of lncRNA, stable trans-
fection is challenging, but some investigators have sug-
gested the use of CRISPR-activation technology to stably
increase the expression of an lncRNA in vitro34,35. Further
experiments examining miRNA, gene expression, and
proliferations markers in the xenograft tumors is warranted.
In conclusion, we identified and validated that ZFAS1
can regulate EMT through a reciprocal interaction with
both miR-200b and miR-200c. Knockdown of ZFAS1 can
lead to a less aggressive phenotype in colon cancer cell
lines, reduction in the mesenchymal marker vimentin, and
an increase in the epithelial marker E-cadherin. This
indicates that ZFAS1 is a major regulator of cancer
aggressiveness and could be a target for therapeutic
intervention in the future.
Methods
A detailed methods section is described in the Supple-
mentary Methods
Ethics statement
This study was approved by the institutional review
board of the University of Louisville and the Institutional
Animal Care and Use Committee of the University of
Louisville.
The Cancer Genome Atlas and Gene Expression Omnibus
(GEO)
The raw sequencing data for colon adenocarcinoma
patients were identified from the Genomic Data Com-
mons portal (https://portal.gdc.cancer.gov/). An R pack-
age “edgeR” was used to identify differentially expressed
genes between a 40 patient subset that had both colon
adenocarcinoma and normal colon epithelium RNA-seq
data files36,37. Heatmap was generated using MORPHEUS
(https://software.broadinstitute.org/morpheus).
Two paired data sets (colon cancer tissue and normal
colon mucosa from the same patient) GSE104836 (N=
10) and GSE95132 (N= 10), and one unpaired data set
(colon cancer tissue and normal colon mucosa from dif-
ferent patients), GSE103512 (N= 70), were downloaded
from the GEO database.
Bioinformatics analysis
Each lncRNA was entered to the bioinformatics pre-
diction program DIANA-lncBASE v2.0 (ref. 9). lncRNA
targets and signaling pathways were identified using
Ingenuity Pathway Analysis (Qiagen, Hilden Germany.)
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Patient samples and laser capture microdissection
Fresh frozen samples of paired colon adenocarcinoma
and normal adjacent colon epithelium from 23 patients
were obtained from the University of Louisville Surgical
Biorepository. Tissue sections were mounted on
negatively-charged slides and stained using the Applied
Biosystems Arcturus Staining Kit (Thermo Fisher Scien-
tific, Bedford, MA). The ArcturusXTTM Laser Capture
Microdissection System was used to isolate the tissue of
interest. RNA was extracted using the PicoPureTM RNA
Isolation Kit (Thermo Fisher Scientific, Waltham, MA).
Cell lines
The HT29 (ATCC® HTB-38TM), SW480 (ATCC®
CCL-228TM), and Caco2 (ATCC® HTB-37TM) colon
adenocarcinoma cell lines were purchased new from the
American Type Culture Collection (Manassas, VA). Cell
lines were authenticated using Short Tandem Repeat
profiling (ATCC, Manassas VA) and tested for myco-
plasma using the MycoFluorTM Mycoplasma Detection
Kit (Life Technologies, Carlsbad, CA).
RNA interference
Small interfering RNA (siRNA) (DharmaconTM, Lafay-
ette, CO), miRNA mimics (DharmaconTM) and miRNA
antagomirs (Life Technologies) were purchased (Supple-
mentary Table 1). All transfections were performed using
Dharmafect-1 transfection reagent (DharmaconTM).
RNA extraction
The Protein and RNA Isolation SystemTM (Life Tech-
nologies®) was used to extract nuclear and cytoplasmic
compartment RNA. Total RNA extracted using the Qia-
gen miRNeasy Mini kit (Qiagen). RNA concentration and
purity were assessed using Nanodrop® 2000 spectro-
photometry (Thermo Fisher Scientific).
Real-time quantitative polymerase chain reaction
(RT-qPCR)- mRNA and lncRNA quantification
Complementary DNA (cDNA) was generated using the
SuperscriptTM IV VILOTM Master Mix (Life Technolo-
gies). qPCR was performed using TaqMan Fast Advanced
Master Mix (Life Technologies) and specific TaqMan®
probes (Supplementary Table 2). The gene expression
levels were normalized to GAPDH.
miRNA quantification
cDNA was generated from RNA samples using the
TaqMan® miRNA reverse transcription kit (Life Tech-
nologies). qPCR was performed using cDNA and specific
TaqMan® miRNA probes (Supplementary Table 2). The
miRNA levels were normalized to U6.
All reactions were performed on a Step-One Plus RT-
qPCR system (Life Technologies), and a cycle threshold
(Ct) of 0.1 was used to calculate ΔCt values for analysis
using the comparative ΔCt method38.
Western blotting
Cells were lysed using radio immune-precipitation assay
buffer and protein concentration determined using the
bicinchoninic acid assay. The primary antibodies are listed
in Supplementary Table 3. Cell lysates were separated by
NuPAGE® MOPS SDS, transferred to a nitrocellulose
membrane, and developed using a ChemiDoc MP imager
(BioRad, Hercules, CA).
Cell proliferation and viability
HT29, SW480, and Caco2 cells were plated at a con-
centration of 1 × 105 cells/well in 2% Fetal Bovine Serum
(FBS) supplemented media. The media was changed to
10% FBS supplemented media after 24 h. Daily cell counts
and percentage of viable cells, using Trypan blue, were
obtained every 24 h from 0 to 120 h using an automatic cell
counter (TC20TM Bio-Rad Laboratories, Hercules, CA).
Scratch assay
HT29 and SW480 cells were plated at 1 × 106 cells/well
in a 12-well plate. A scratch was made using a sterile 20 μl
pipette tip. Photos (Nikon Eclipse TS100) were taken
every 24 h from 0 to 120 h or until complete scratch
closure (×4 magnification). The percentage scratch clo-
sure for each time point was compared to 0 h.
Transwell migration and invasion
SW480 cells were seeded at 2 × 105 cells/well, and HT29
cells were seeded at 5 × 105 cells/well into a transwell
migration (COSTAR, 8.0 μm pore polycarbonate mem-
brane) or invasion insert (COSTAR, 8.0 μm pore Corning
BioCoat Matrigel Invasion Chambers), as per the manu-
facturer’s instructions. Complete media (supplemented
with 10% FBS) was the chemoattractant, and plates were
incubated at 37 °C for 24 h. Each insert was stained with
the Diff-Quik staining kit (Electron Microscopy Sciences,
Hatfield, PA), and six representative images were taken
(×10 magnification). Migrated cells in each field were
manually counted.
In vivo tumor growth
Six-week old male Nu/J mice were purchased from the
Jackson Laboratory (Bar Harbor, Maine). Each mouse was
injected with 5 × 106 cells in 200 µL PBS. Mass volume
was calculated using the formula: Volume= 0.5 × long-
itude diameter × (latitudinal diameter)2, every 3 days up to
14 days post mass identification.
Statistical analysis
All reactions were performed in duplicate, with the
average being used for analysis. Data are presented as
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median (interquartile range). The chi-squared test, or
Fischer’s exact test, were used to compare categorical
variables. The Mann–Whitney U test and Wilcoxon
signed-rank test were used to compare continuous vari-
ables. Differences in overall survival were compared with
the Log-rank test. Statistical analysis was performed using
SPSS v26.0 (IBM Corp, Armonk, NY). Graphs were created
using GraphPad Prism v6.01 (Graphpad Software Inc. La
Jolla, CA). Statistical significance was defined as p < 0.05.
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